The United Nations Office at Geneva
Multimedia Newsroom
STORYLINE
Injectable HIV medicines deal to provide access to generic lifesaver in developing nations
A landmark agreement has been reached allowing for the production of low-cost, injectable HIV medicines in some 90 developing countries where more the majority of infections occur, UNITAID said on Friday.
Selected manufacturers will be able to develop, manufacture and supply lower-cost generic versions of long-acting Cabotegravir (CAB-LA), in line with a deal reached with pharmaceutical firm ViiV Healthcare (ViiV).
“The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to Cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries,” said UNITAID spokesperson Hervé Verhoosel.
The deal is significant because Cabotegravir injections are only needed once every few months. Increasing its supply at a cost that is affordable to low-income countries could help to overcome the stigma that’s associated with taking daily HIV pills - and the burden of having to remember to take them.
“In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV won’t ask for any royalty on the product and for 10 of those countries, ViiV is asking for a smaller-than-usual royalty,” Mr. Verhoosel explained.
The agreement comes after UNITAID-led discussions began in May this year with ViiV, a subsidiary of pharma giant GlaxoSmithkline. It is only seven months since Cabotegravir LA received regulatory approval.
But the process of selecting the companies that will develop, manufacture and supply generic versions of Cabotegravir will take much longer.
“This product will not be there for everybody, that’s first for people who are there the most at risk,” said Mr. Verhoosel, who noted that the cost of the medicine in the US when it comes onstream there “really soon”, was likely to be around $20,000. “That’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
According to UNITAID, the deal offers the possibility of making the injectable prophylactic medicine available in 90 countries where more than 70 per cent of all new HIV infections occurred in 2020.
Up to three drug manufacturers will be licensed to develop the product on a generic basis to avoid supply and distribution issues. “That’s done in a way that we’re sure (that) one, it’s easy for logistics, two…availability, and three, of course, that it will help to bring the cost of the generic version down”, said Mr. Verhoosel.
ends
STORY: Injectable HIV Prevention Medicines Deal - UNITAID
TRT: 02’05”
SOURCE: UNTV CH
RESTRICTIONS: NONE
LANGUAGE: ENGLISH/NATS
ASPECT RATIO: 16:9
DATELINE: Friday 29 July 2022, GENEVA, SWITZERLAND
SHOTLIST
- Medium shot, UN Geneva flag alley.
- Wide shot, press room with panel of speakers, journalists, TV camera on tripod.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries.”
- Medium shot, lateral, podium speakers.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV (ViiV Healthcare) don’t ask any royalty on the product and for 10 of those countries ViiV is asking for a smaller-than-usual royalty.”
- Wide shot, journalists, TV camera, light panel.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This product will not be there for everybody, that’s first for people who are there the most at risk. That’s a product that’s available in the US, and the price of that product for one year in the US for example is approximately 20,000 US dollars, and that’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
- Medium shot, journalists seated at tables, TV camera.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This licence will actually give the option to three different generic manufacturers to develop the product on a generic base. That means that the price that those companies will have we don’t know yet, but that will not only be one company, that will be three different companies and that’s done in a way that we’re sure one, that it’s easy for logistics, two, that ensuring availability, and three, of course, that it will help to bring the cost of the generic version down.”
- Medium shot, journalists.
- Wide shot, journalists, TV camera and light panel.
- Medium shot, journalist.
- Medium shot, journalists, side shot.
Similar Stories
1
1
1
Edited News | UNHCR
More than 280,000 people have now been displaced by fighting in Yemen and many vulnerable people are unable to access lifesaving relief because it is too dangerous to do so, the UN refugee agency (UNHCR) said on Friday.
1
1
1
Edited News | UN
Tour guides at UN Geneva turned heads at the Palace of Nations on Thursday as they unveiled stylish new uniforms, designed in partnership with leading Italian sustainable fashion designers and manufacturers.
1
1
1
Edited News | OCHA , UNICEF , WFP
Aid agencies warned on Friday of the fast-developing humanitarian emergency inside Taiz City in Yemen, which has been encircled by de facto Houthi forces fighting government troops along the country’s west coast.
2
17
1
2
Edited News , Press Conferences , Images | OCHA , WMO
Two UN agencies teamed up on Wednesday to issue an appeal for immediate assistance to help communities already being impacted by the strongest El Niño on record.
3
16
2
2
Edited News , B-roll , Conferences , Images | UNITED NATIONS , UNOG
Sixth Consultative Meeting on Enhancing Coordination of Peace Initiatives and Efforts for Sudan
1
1
1
Edited News | UNICEF , WHO , UNHCR
Yemen war continues to force families from homes amid hunger and disease
More than 250,000 people have now fled renewed fighting in Yemen, the UN said on Tuesday, citing particular concern for those sheltering in the southwestern city of Taiz and the wider governorate, where access is “essentially blocked”.
1
1
1
Edited News | UNICEF
A little over one year since a ceasefire agreement was announced between Hamas fighters and Israel, more than 340 children have been reported killed and hundreds more injured, the UN Children’s Fund, UNICEF, said on Friday.
1
1
1
Edited News | UNICEF , IFRC
Six weeks after Nepal’s deadly flooding disaster, communities are still struggling to rebuild their lives, but they will need sustained help as global warming increases the risk of another Himalayan catastrophe, the UN Children’s Fund (UNICEF) said on Friday.
1
1
1
Edited News | WHO
In suspected Russia plague death, testing and monitoring underway – WHO
The death of a lab worker in Russia’s Siberia region has sparked concerns about plague being the cause, the UN World Health Organization (WHO) said on Tuesday, adding that it was following the situation closely.
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Friday provided and oral update to the 63rd session of the Human rights Council on Ukraine.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Friday provided and oral update to the 63rd session of the Human rights Council on the human rights situation in Haiti.
1
1
1
Edited News | WHO
Repeated delays in bringing lifesaving medicines, prosthetics and more from Israel into Gaza risk having devastating consequences on Palestinians who urgently need them in the wartorn enclave, the UN World Health Organization (WHO) said on Friday. “A truck full of non-priority supplies or the right supplies arriving too late, doesn't save lives. That's the question that actually matters," said Dr Reinhilde Van De Weerdt, WHO Representative in the OPT.